Stocktradesmoon
Nov 2, 6:25 PM
$ABCL
Here’s exactly what I’m watching.
November 9: Q3 earnings and pipeline update.
November 11: Stifel Healthcare Conference.
November 16: Jefferies Global Healthcare Conference in London.
But the real question is clinical execution.
The drug targets NK3R and is being developed as a long-acting, non-hormonal treatment for menopausal hot flashes.
After positive Phase 2 topline results in August, I want clarity on the next clinical development steps, durability of response and the potential for monthly dosing.
Financially, the last reported quarter showed
$565M+ in cash and marketable securities, plus
$110M in available government funding.
And analysts are paying attention: UBS initiated coverage at Buy with an
$18 target, JPMorgan at Overweight with
$17.
My view: ABCL635 has already delivered the first major clinical validation. Now management needs to demonstrate how that translates into a credible path toward commercialization.
November 9 is the next test.
0 replies
